{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:06:49Z","timestamp":1767892009529,"version":"3.49.0"},"reference-count":8,"publisher":"Hogrefe Publishing Group","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p> Zusammenfassung. Eine Hyperthyreose resultiert entweder aus Steigerung der Synthese und Sekretion von Schilddr\u00fcsenhormonen oder aus deren Freisetzung bei der Destruktion von Schilddr\u00fcsengewebe, wie auch durch \u00fcberm\u00e4ssige exogene Levothyroxin-Gabe. Der Begriff \u00abThyreoiditis\u00bb umfasst eine heterogene Gruppe von Schilddr\u00fcsenentz\u00fcndungen, die durch Parenchymdestruktion zur unregulierten Freisetzung von Schilddr\u00fcsenhormonen (\u00abFreisetzungs-Hyperthyreose\u00bb) f\u00fchren. Diese seltenere Hyperthyreose-Ursache muss differenzialdiagnostisch erkannt werden, da prim\u00e4r eine symptomatische Therapie im Vordergrund steht. Bedingt durch die Pathophysiologie ist eine thyreostatische Therapie unwirksam. Der typische triphasische Verlauf der Funktionslage rechtfertigt ein exspektatives Vorgehen, insbesondere w\u00e4hrend der ersten selbstlimitierenden hyperthyreoten Phase. Nach der folgenden, meist passageren hypothyreoten Funktionslage wird innerhalb eines Jahres wieder eine euthyreote Funktionslage erreicht. Doch kann eine permanente Hypothyreose resultieren, was die Notwendigkeit regelm\u00e4ssiger Kontrollen verdeutlicht und bei Bedarf eine Levothyroxin-Therapie erfordert. <\/jats:p>","DOI":"10.1024\/1661-8157\/a003078","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T07:05:40Z","timestamp":1540969540000},"page":"1187-1192","source":"Crossref","is-referenced-by-count":3,"title":["CME: Hyperthyreose bei Thyreoiditiden"],"prefix":"10.1024","volume":"107","author":[{"given":"Lea","family":"Slahor","sequence":"first","affiliation":[{"name":"Endokrinologie\/Diabetologie, Luzerner                     Kantonsspital, Luzern"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","reference":[{"key":"c1","unstructured":"Kravets I:                         Hyperthyroidism: Diagnosis and treatment.                         Am Fam Physician 2016;                         93:                     363\u2013370."},{"key":"c2","doi-asserted-by":"crossref","unstructured":"Mencoi F,                             Marcocci C,                             Marino M:                         Diagnosis and classification of Graves\u2019                         disease. Autoimmun                         Rev 2014; 13:                         398\u2013402.","DOI":"10.1016\/j.autrev.2014.01.013"},{"key":"c3","doi-asserted-by":"crossref","unstructured":"Journy MY,                             Bernier MO,                             Doody MM,                         et al.: Hyperthyroidism, hypothyroidism, and                         cause-specific mortality in a large cohort of women.                         Thyroid 2017; 27:                         1001\u20131010.","DOI":"10.1089\/thy.2017.0063"},{"key":"c4","doi-asserted-by":"crossref","unstructured":"Abdulwahid MS,                             Kakamad FH,                             Rawezh QS,                         et al.: Subacute thyroiditis causing thyrotoxic                         crisis: a case report with literature review.                         Int J Surg Case Rep 2017;                         33:                     112\u2013114.","DOI":"10.1016\/j.ijscr.2017.02.041"},{"key":"c5","doi-asserted-by":"crossref","unstructured":"Samuels MH:                         Subacute, silent and postpartum thryoiditis.                         Med Clin N Am 2012;                         96:                     223\u2013233.","DOI":"10.1016\/j.mcna.2012.01.003"},{"key":"c6","doi-asserted-by":"crossref","unstructured":"Pearce EN,                             Farwell AP,                             Braverman LE:                         Thyroiditis. N Engl J                         Med 2003; 348:                         2646\u20132655.","DOI":"10.1056\/NEJMra021194"},{"key":"c7","doi-asserted-by":"crossref","unstructured":"Delivanis DA,                             Gustafson MP,                             Bornschlegel S,                         et al.: Pembrolizumab-induced                         thyroiditis. J Clin Endocrinol                         Metab 2017; 102:                         2770\u20132780.","DOI":"10.1210\/jc.2017-00448"},{"key":"c8","doi-asserted-by":"crossref","unstructured":"Fatourechi V,                             Aniszewski JP,                             Guiti Z,                         et al.: Clinical features and outcome of                         subacute thyroiditis in an incidence cohort. J                         Clin Endocrinol Metab 2003; 88:                         2100\u20132105.","DOI":"10.1210\/jc.2002-021799"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T09:51:27Z","timestamp":1615974687000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":8,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1024\/1661-8157\/a003078"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003078","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}